These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 17429091)

  • 1. Sunitinib and hypothyroidism.
    Wolter P; Dumez H; Schöffski P
    N Engl J Med; 2007 Apr; 356(15):1580; author reply 1580-1. PubMed ID: 17429091
    [No Abstract]   [Full Text] [Related]  

  • 2. Fatigue with sunitinib-induced hypothyroidism.
    Senior K
    Lancet Oncol; 2007 Feb; 8(2):101. PubMed ID: 17288042
    [No Abstract]   [Full Text] [Related]  

  • 3. [Treatment with sunitinib and hypothyroidism--a case report and overview of literature].
    Kreze A; Stáhalová V; Zadrazilová A; Koskuba J; Kosák M
    Klin Onkol; 2009; 22(4):176-8. PubMed ID: 19731880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
    Feldman DR; Martorella AJ; Robbins RJ; Motzer RJ
    J Natl Cancer Inst; 2007 Jun; 99(12):974-5; author reply 976-7. PubMed ID: 17565156
    [No Abstract]   [Full Text] [Related]  

  • 5. How does sunitinib cause hypothyroidism?
    Hershman JM; Liwanpo L
    Thyroid; 2010 Mar; 20(3):243-4. PubMed ID: 20187779
    [No Abstract]   [Full Text] [Related]  

  • 6. Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
    Garfield DH; Hercbergs A; Davis PJ
    J Natl Cancer Inst; 2007 Jun; 99(12):975-6; author reply 976-7. PubMed ID: 17565154
    [No Abstract]   [Full Text] [Related]  

  • 7. Fatal liver failure in a patient treated with sunitinib for renal cell carcinoma.
    Mermershtain W; Lazarev I; Shani-Shrem N; Ariad S
    Clin Genitourin Cancer; 2013 Mar; 11(1):70-2. PubMed ID: 23063577
    [No Abstract]   [Full Text] [Related]  

  • 8. Tumour lysis syndrome in a patient with renal-cell carcinoma treated with sunitinib malate.
    Nicholaou T; Wong R; Davis ID
    Lancet; 2007 Jun; 369(9577):1923-4. PubMed ID: 17560435
    [No Abstract]   [Full Text] [Related]  

  • 9. Pazopanib outscores sunitinib on tolerability.
    Cancer Discov; 2014 Jan; 4(1):OF8. PubMed ID: 24402960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extreme hypothyroidism associated with sunitinib treatment for metastatic renal cancer.
    Del Fabbro E; Dev R; Cabanillas ME; Busaidy NL; Rodriguez EC; Bruera E
    J Chemother; 2012 Aug; 24(4):221-5. PubMed ID: 23040687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe rhabdomyolysis during sunitinib treatment of metastatic renal cell carcinoma. A report of two cases.
    Ruggeri EM; Cecere FL; Moscetti L; Doni L; Padalino D; Di Costanzo F
    Ann Oncol; 2010 Sep; 21(9):1926-1927. PubMed ID: 20729535
    [No Abstract]   [Full Text] [Related]  

  • 12. Benefits of pazopanib over sunitinib for renal cell carcinoma.
    Granovetter M
    Lancet Oncol; 2016 Mar; 17(3):e93. PubMed ID: 26853821
    [No Abstract]   [Full Text] [Related]  

  • 13. Sunitinib as adjuvant therapy for renal cell carcinoma.
    Baker H
    Lancet Oncol; 2016 Nov; 17(11):e485. PubMed ID: 27773485
    [No Abstract]   [Full Text] [Related]  

  • 14. Lower limbs erosions induced by sunitinib.
    Kluger N; Chapelle A; Jacot W; Guillot B
    Acta Derm Venereol; 2011 May; 91(3):360-1. PubMed ID: 21103845
    [No Abstract]   [Full Text] [Related]  

  • 15. Home blood-pressure monitoring in patients receiving sunitinib.
    Azizi M; Chedid A; Oudard S
    N Engl J Med; 2008 Jan; 358(1):95-7. PubMed ID: 18172185
    [No Abstract]   [Full Text] [Related]  

  • 16. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
    Rini BI; Tamaskar I; Shaheen P; Salas R; Garcia J; Wood L; Reddy S; Dreicer R; Bukowski RM
    J Natl Cancer Inst; 2007 Jan; 99(1):81-3. PubMed ID: 17202116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Tumor lysis syndrome in a patient with a renal carcinoma treated with sunitinib].
    Rodríguez-Reimúndes E; Perazzo F; Vilches AR
    Medicina (B Aires); 2011; 71(2):158-60. PubMed ID: 21550933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rectal perforation after two years of treatment with sunitinib for metastatic kidney cancer.
    Bladé JS; Bourgouin S; Romeo É; Boudin L; de Jauréguiberry JP
    Presse Med; 2014 Nov; 43(11):1293-5. PubMed ID: 24999082
    [No Abstract]   [Full Text] [Related]  

  • 19. Sunitinib induces hypothyroidism with a markedly reduced vascularity.
    Makita N; Miyakawa M; Fujita T; Iiri T
    Thyroid; 2010 Mar; 20(3):323-6. PubMed ID: 20187785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sunitinib-induced thyrotoxicosis - a not so rare entity.
    Jazvić M; Prpić M; Jukić T; Murgić J; Jakšić B; Kust D; Prgomet A; Bolanča A; Kusić Z
    Anticancer Res; 2015 Jan; 35(1):481-5. PubMed ID: 25550591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.